Page last updated: 2024-09-03

imatinib mesylate and Benign Neoplasms

imatinib mesylate has been researched along with Benign Neoplasms in 306 studies

Research

Studies (306)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	178 (58.17)	29.6817
2010's	102 (33.33)	24.3611
2020's	26 (8.50)	2.80

Authors

Authors	Studies
Bharathi, EV; Dastagiri, D; Kamal, A; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Reddy, JS; Reddy, MK; Reddy, TL; Sagar, MV	1
Awadasseid, A; Jiang, SK; Liang, J; Sugiyama, H; Wu, YL; Xiong, XQ; Xu, L; Zhang, M; Zhang, W; Zhao, XY	1
Johnson, GL; Ramos, AF; Rosner, MR; Yesilkanal, AE	1
Chatelut, E; Clarke, WA; Fotoohi, AK; Larson, RA; Martin, JH; Mathijssen, RHJ; Salamone, SJ	1
Fujii, T; Kitahara, S; Kobayashi, S; Matsui, T; Matsunaga, T; Ohno, N; Sahara, N; Sakamoto, N	1
Bastos, M; Boechat, N; Dantas, R; Moura, S; Neto, J; Oliveira, A; Pimentel, L; Silva-Jr, F	1
Bertoletti, L; Bin, V; Delavenne, X; Hodin, S; Lafaie, L; Saïb, S	1
Li, CW; Lin, D; Mi, YC; Tian, Z; Wan, L; Wang, Z	1
Attrill, E; Brown, LS; Cashion, JM; Courtney, JM; Foster, CG; Howells, DW; King, NE; Premilovac, D; Sutherland, BA	1
Nathan, J; Palanivel, G; Shameera, R	1
Dirkson, A; Gelderblom, H; Kraaij, W; van Oortmerssen, G; Verberne, S	1
Anshu, A; Das, R; Jamwal, M; Lad, D; Rathore, S; Sreedharanunni, S; Virk, H	1
Cho-Vega, JH; Loghavi, S	1
Coltro, G; Santi, R	1
Berry, A; Constantine, G; Khoury, P; Klion, AD; Kuang, FL; Lane, AA; Makiya, M; Maric, I; Pongdee, T; Rheinbay, E; Sun, X; Thumm, L; Wetzler, L; Yoon, P	1
Agarbati, S; Benfaremo, D; Moroncini, G; Mozzicafreddo, M; Paolini, C; Svegliati Baroni, S	1
Dal Cin, P; Ebert, BL; Grinshpun, DE; Hobbs, GS; Iafrate, AJ; Jan, M; Nardi, V; Sykes, DB; Villalba, JA	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Blum, S; Brouland, JP; Chalandon, Y; Comoli, P; Comte, D; Du Pasquier, R; Dunet, V; Livio, F; Opota, O; Spertini, O; Tirefort, Y	1
Chen, P; Liu, G; Liu, T; Ouyang, R; Shen, C; Zhou, L	1
Triche, TJ	1
Hoemberger, M; Kern, D; Pitsawong, W	1
Byran, G; Lakshmanan, K	1
Gota, V; Joshi, H; Patil, V; Ramaa, CS; Tilekar, K; Upadhyay, N	1
Barkoh, BA; Bueso-Ramos, CE; Chen, W; Fang, H; Futreal, A; Gupta, SK; Jain, N; Khoury, JD; Loghavi, S; Luthra, R; Mao, X; Medeiros, LJ; Patel, KP; Routbort, M; Tang, G; Wang, SA; Yang, RK; Zhang, J	1
Dholam, K; Gupta, L; Gurav, SV; Janghel, Y	1
Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G	1
Allison, J; Bailey, A; Bass, A; Bean, S; Falchook, G; Fu, S; Hong, DS; Janku, F; Karp, D; Lim, J; Meric-Bernstam, F; Montez, S; Naing, A; Piha-Paul, S; Reilley, MJ; Sharma, P; Subbiah, V; Tsimberidou, A; Vence, L	1
Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML	1
Naseer, MM; Rahman, MSU; Saeed, A; Shoaib, M	1
Nair, P	1
Cardoso, E; Csajka, C; Schneider, MP; Widmer, N	1
Ahmed, G; Kim, SB; Shay, JW; Terman, JR; Yoon, J	1
Allard, M; Bellesoeur, A; Blanchet, B; Cardoso, E; Rousseau, B	1
Baker, SD; Jeon, JY; Sparreboom, A	1
Boehm, JS; Hong, AL; Painter, CA; Sharifnia, T	1
Burney, IA; Lakhtakia, R	1
Asmis, T; Gilbert, S; Pysyk, CL	1
Chang, JH; Choi, HG; Gautam, M; Jeong, JH; Jiang, L; Kim, JO; Ku, SK; Ou, W; Soe, ZC; Thapa, RK; Yong, CS	1
Abouzid, KA; Fawzy, IM; Ismail, NS; Lasheen, DS; Youssef, KM	1
Dusetzina, SB; Keating, NL; Rotenstein, LS	1
Asami, Y; Crump, A; Ōmura, S	1
Garcia-Gonzalez, P; Novakowski, AK; Stergachis, A; Wrigglesworth, M	1
Bencze, J; Gergely, PA; Gombos, K; Hortobágyi, T; Kurucz, A; Murnyák, B; Varjas, T	1
Tempero, M	1
Abruzzese, E; Bernardi, S; Binotto, G; Bonifacio, M; Iurlo, A; Russo, D; Tiribelli, M; Zanaglio, C	1
Cho, YS; Gwak, HS; Han, JM; Yee, J	1
Kannan, N; Oruganty, K	1
Buclin, T; Csajka, C; Gotta, V; Widmer, N	1
Chatterjee, P	1
Cook, SJ; Sale, MJ	1
Despas, F; Laurent, G; Roche, H	1
Coombs, J; Kruse, M; Parthan, A; Sasane, M; Taylor, D	1
Lin, YL; Roux, B	1
Adenis, A; Amela, EY; Blay, JY; Bui-Nguyen, B; Cassier, PA; Chauzit, E; Clisant, S; Fournier, C; Italiano, A; Molimard, M; Penel, N; Ray-Coquard, I; Tresch-Bruneel, E	1
Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N	1
Druker, BJ	4
Waller, CF	2
Brazzelli, V; Croci, G; Grasso, V; Vassallo, C	1
Gravitz, L	2
Bourzac, K	1
Aittokallio, K; Alpay, K; Farshchian, M; Hietanen, S; Kähäri, VM; Kallio, M; Sandholm, J; Siljamäki, E; Tuomela, J	1
Belmont, P; Mariaule, G	1
Agafonov, RV; Buosi, V; Kern, D; Otten, R; Wilson, C	1
Bonkobara, M	1
Wissing, MD	1
Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W	1
Abdi, M; Amini, S; Azadi, NA; Ghaderi, B; Salimizand, H	1
Nishio, K; Togashi, Y	1
Tanigawara, Y	1
Brullo, C; Grossi, G; Musumeci, F; Sanna, M; Schenone, S	1
Baruzzi, A; Berton, G; Chignola, R; Lorenzetto, E; Remelli, S; Sega, M	1
Block, J; Meng, F; Wu, G	1
Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H	1
Amgoth, C; Dharmapuri, G; Kalle, AM; Paik, P	1
Eckstein, N; Frötschl, R; Haas, B; Weber-Lassalle, K	1
Bhattacharya, M; Chakraborty, C; Lee, SS; Patra, BC; Sharma, AR; Sharma, G	1
Bedwell, C; Greystoke, B; McGregor, AK; Oakes, R; Wood, K	1
Doroshow, JH; Parchment, RE	1
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A	1
Tuma, RS	1
Gasparini, G; Longo, R	1
Becker, H; Berg, T; Binder, M; Dierks, C; Duque-Afonso, J; Hackanson, B; Lairmore, MD; Lübbert, M; Martens, U; Mertelsmann, R; Schäfer, HS; Schnitzler, M; Zeiser, R	1
Dingermann, T; Laufer, S; Winckler, T	1
Franke, RM; Sparreboom, A	1
Sakai, H; Takeuchi, S	1
Cogan, E; Roufosse, F	1
Iwata, C; Kano, MR; Kataoka, K; Komuta, Y; Miyazono, K; Morishita, Y; Oka, M; Ouchi, Y; Shirai, YT	1
Bird, R; Henden, A; Keane, C	1
Adamson, PC	1
Al Rashid, S; Bristow, RG; Choudhury, A; Jalali, F; Kiltie, AE; Ran, J; Supiot, S; Zhao, H	1
Eck, MJ; Manley, PW	1
Boderet, F; Bosq, J; Capdeville, R; Chatelut, E; Doz, F; Emile, JF; Frappaz, D; Geoerger, B; Geoffray, A; Hain, S; Kalifa, G; Le Deley, MC; Morland, B; Ndiaye, A; Opolon, P; Pichon, F; Vassal, G	1
Bailey, S; Branson, M; Laird, G; Neuenschwander, B	1
Ergolin, MJ	1
Kapoor, S	1
Belknap, SM; Bennett, CL; Boyle, S; Burdon, R; Djulbegovic, B; Dorr, DA; Edwards, BJ; Georgopoulos, C; Lagman, J; McKoy, JM; Sartor, O; Tallman, MS; Talpaz, M; Weitzman, SA; West, DP	1
Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B	1
Rochat, B	2
Schiff, D; van den Bent, MJ; Wen, PY	1
D'Incalci, M; Damia, G	1
Lydon, N	1
Sawyers, CL	1
Chaput, N; Ménard, C; Tursz, T; Zitvogel, L; Zoubir, M	1
Ashby, CR; Chen, A; Chen, X; Chen, ZS; Hopper-Borge, E; Kuang, YH; Lei, Y; Ouyang, J; Shen, T; Tiwari, AK; Zhou, Y	1
Gauthier, H	1
Marmorstein, R	1
Wang, ZY	1
De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F	1
Adrian, F; Berst, F; Cowan-Jacob, SW; Fabbro, D; Fendrich, G; Furet, P; Gray, NS; Grotzfeld, R; Jahnke, W; Liebetanz, J; Manley, PW; Marzinzik, A; Mestan, J; Pelle, X; Strauss, A; Szyttenholm, A; Warmuth, M; Zhang, J	1
Aleksandrov, A; Simonson, T	1
Dorsch, M; Sellers, WR; Stegmeier, F; Warmuth, M	1
Golub, T	1
Venkatraman, P	1
Druker, B	1
Brüggen, J; Conus, N; Cullinane, C; Hui, Y; Jackson, S; Manley, PW; McArthur, GA; Natoli, A	1
Klein, S; Levitzki, A	2
Blobe, GC; Dugan, E; Favaro, J; Fernando, NH; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Petros, WP; Truax, R	1
Saijo, N	1
Kong, D; Yamori, T	1
Bernheim, A	1
Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J	1
Baker, LH; Chenevert, T; Chugh, R; Karantza, V; Mehnert, J; Moss, RA; Poplin, EA; Saraiya, B; Savkina, N; Stein, MN	1
Harrop, R; Shingler, W	1
Biollaz, J; Buclin, T; Decosterd, LA; Widmer, N	1
Chaput, N; Flament, C; LeCesne, A; Marty, V; Pautier, P; Ribrag, V; Robert, C; Soria, JC; Viaud, S; Vielh, P; Zitvogel, L; Zoubir, M	1
Chu, DT	1
Angiolini, M	1
Burris, H; Doss, H; Greco, FA; Hainsworth, J; Infante, J; Jones, S; Spigel, D; Thompson, D	1
Bernstein, ML	1
Chan, WL; Chang, JG; Chang, WH; Lee, CC; Lin, YH; Wu, YC	1
Geoerger, B; Leblond, P	1
Bandyopadhyay, S; Chile, S; Joshi, K; Monahar, S; Pal, BC; Sharma, S; Wagh, V	1
Caponigro, F; Ciarmiello, A; Milano, A; Perri, F	1
Schmidt, C	1
Crane, K	1
Bugnon, O; Jeanneret, LA; Lüthi, F; Schneider, MP; Troxler, S	1
Croce, CM	1
Demoulin, JB; Medves, S	1
Beckeringh, JJ; Boven, E; Hugtenburg, JG; Timmers, L; van Herk-Sukel, MP	1
Daw, HA; Peerzada, MM; Spiro, TP	1
Adenis, A; Bay, JO; Bertucci, F; Blay, JY; Bouché, O; Cassier, P; Chevreau, C; Clisant, S; Collard, O; Fournier, C; Italiano, A; Kalbacher, E; Kramar, A; Penel, N	1
Benesch, M; Burdach, S; Frühwald, M; Graf, N; Greulich, N; Grunewald, TG; Kontny, U; Kordes, U; Metzler, M; Mittler, U; Rutkowski, S; Scheurlen, W; Schmidt, W; Stachel, D	1
Aitelhaj, M; Boutayeb, A; Boutayeb, S; Boutayeb, W; Errihani, H; Mesmoudi, M; Mrabti, H; Zakkouri, FZ	1
Airley, R	1
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S	1
Ho, WL; Wong, H; Yau, T	1
Beumer, JH; Cotarla, I; Deeken, J; Egorin, MJ; Elston, B; Firozvi, K; Hartley, ML; He, AR; Hwang, J; Koh, EY; Liu, M; Malik, S; Marshall, JL; Pishvaian, MJ; Slack, R; Strychor, S	1
Levitzki, A	2
Blanc, J; Geney, R; Menet, C	1
Branford, S	1
Al-Saeedi, FJ; Luqmani, YA; Mathew, PM	1
Hickman, JA; Lazo, JS	1
Fabbro, D; Matter, A; Parkinson, D	1
Blay, JY; Ray-Coquard, I	1
Sugimura, T	1
Couzin, J	1
Scoazec, JY	1
Garber, K	3
Workman, P	1
Britten, CD; Ma, BB; Siu, LL	1
Buchdunger, E; Cowan-Jacob, SW; Fabbro, D; Fendrich, G; Furet, P; Manley, PW; Meyer, T; Zimmermann, J	1
Akiyama, S	4
Westwell, AD	2
Schwartz, RS	1
Hingorani, SR; Tuveson, DA	1
Blasberg, RG; Tjuvajev, JG	1
George, D	1
Fischer, OM; Hart, S; Streit, S; Ullrich, A	1
Kim, JA	1
Abou-Jawde, R; Alemany, C; Choueiri, T; Mekhail, T	1
Fleischer-Black, M; Strom, S	1
Goldman, B	1
Inui, A	1
Shiotsu, Y	1
Duhé, RJ; Mamoon, NM; Smith, JK	1
Arteaga, CL; Roberts, RB; Threadgill, DW	1
Haydon, RC; He, TC; Zhou, L	1
Druker, BJ; Lydon, NB	1
Kim, R; Toge, T	1
Agarwal, NK; Arora, B; Gupta, SK; Kumar, L; Mathur, R; Velpandian, T	1
Jones, RJ; Matsui, WH; Smith, BD	1
Rowinsky, EK	1
Fletcher, JA	1
Pietras, K	1
Nadal, E; Olavarria, E	1
Ostman, A	1
Abad, M; Astudillo, A; Balbín, M; Blay, P; Braña, A; Buesa, JM; Campo, E; Freije, JM; García-García, J; Lacave, A; Losa, R; Marco, V; Miquel, R; Sierra, M	1
Ganesan, TS; Madhusudan, S	1
Debiec-Rychter, M; Nasierowska-Guttmejer, A; Nowecki, Z; Ruka, W; Rutkowski, P	1
Dillman, R; Oldham, R	1
Mohindru, M; Verma, A	1
Bhalla, K; Cheng, F; Cuenca, A; Horna, P; Sotomayor, EM; Wang, H; Zheng, Z	1
Gastl, G; Hiddemann, W	1
Bundi, M; Dimitrijevic, S; Dirnhofer, S; Kononen, J; Lugli, A; Mangialaio, S; Mirlacher, M; Sauter, G; Schraml, P; Simon, R; Went, PT	1
Gahmberg, CG; Kervinen, J	1
Cross, NC; Jones, AV	1
Hirotab, S; Kitamura, Y	1
Basile, M; Caponigro, F; de Rosa, V; Normanno, N	1
Favaudon, V; Hennequin, C	1
Attard, G; De Bono, J; Kaye, S; Vidal, L	1
Barwisch, S; Duyster, J; Peschel, C; Speicher, MR; von Bubnoff, N	1
Blay, JY	2
Aulitzky, WE; Oetzel, C; Schwab, M; van der Kuip, H; Wohlbold, L	1
Blum, HE; Geissler, M; Grimm, CF	2
Bernards, R	1
Brok, M; Burger, H; de Boeck, G; de Bruijn, EA; Guetens, G; Nooter, K; Sparreboom, A; van Tol, H; Verweij, J; Wiemer, EA	1
Lin, C; Liu, ZR; Yang, L	1
Armand, JP; Boige, V; Escudier, B; Le Cesne, A; Le Chevalier, T; Lhomme, C; Malka, D; Pautier, P; Robert, C; Soria, JC; Spatz, A; Wechsler, J	1
Krause, DS; Van Etten, RA	1
Heinemann, V; Hiddemann, W	1
Blaise, D; Gaugler, B; Mohty, M; Olive, D	1
Brownlow, N; Dibb, NJ; Domin, J; Taylor, JR	1
Boros, LG; Serkova, N	1
Frantz, S	1
Roskoski, R	1
Geoerger, B; Grill, J; Hartmann, O; Jubert, C; Vassal, G	1
Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F	1
Iwasa, Y	1
Czerwenka, K; Handl, C; Hudelist, G; Kubista, E; Lamm, W; Mueller, R; Singer, CF	1
Miki, Y; Nagasaki, K; Shimoji, T	1
Sun, Y; Wang, Y	1
Appleman, LJ; Demetri, GD; Desai, J; George, S; Manola, J; Paul Eder, J; Ryan, DP	1
De Boeck, G; de Bruijn, EA; de Wever, I; Guetens, G; Highley, M; Prenen, H; van Oosterom, AT	1
Jachimczak, P	1
Dirnhofer, S; Went, P; Zimpfer, A	1
Smyth, MJ	1
Baselga, J	1
Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN	1
Jootar, S; Lassarat, S	1
Ichinose, Y; Maehara, Y; Oda, S; Okamoto, T; Yamanaka, T	1
Mann, DL	1
Schultze, JL	1
Fidler, IJ	1
Fujii, S; Fujimoto, K; Hidaka, M; Kadowaki, N; Kawano, F; Konishi, N; Makita, N; Shimizu, K; Taniguchi, M; Uchiyama, T	1
Curtiss, FR	1
Abbott, LH; Michor, F	1
Arslan, MA; Basaga, H; Kutuk, O	1
Knuth, A; Pestalozzi, BC; Stenner-Liewen, F; Zippelius, A	1
Ahmed, S; Andreoni, F; Boschelli, F; Cleris, L; Coluccia, AM; Donella-Deana, A; Formelli, F; Gambacorti-Passerini, C; Magistroni, V; Marchesi, E; Piazza, R; Puttini, M; Redaelli, S; Scapozza, L	1
Necas, E; Sefc, L; Shchemelinin, I	1
Kamb, A; Lengauer, C; Wee, S	1
Chami, L; Lassau, N; Péronneau, P	1
Kibble, A	1
Corneo, G; Franceschino, A; Gambacorti, C; Gambacorti-Passerini, C; Piazza, R; Pogliani, E; Tornaghi, L	1
Hatfield, A; Owen, S; Pilot, PR	1
Atallah, E; Cortes, J; Kantarjian, H	2
Baccarani, M; Martinelli, G; Rosti, G	1
Adamson, PC; Bernstein, ML; Blaney, SM; Bond, M; Krailo, M; Pappo, A; Schultz, KR	1
Alajez, NM; Bastianutto, C; Busson, P; Li, JH; Liu, FF; Lo, KW; Lunt, SJ; Milosevic, M; Mocanu, JD; Moriyama, EH; Shi, W; van Rooijen, N; Wilson, BC; Yip, KW	1
Heldin, CH; Ostman, A	1
Apperley, JF; Chaidos, A; Kanfer, E	1
Altucci, L; Balducci, L; Irminger-Finger, I	1
Daud, AI; Homsi, J	1
Sparreboom, A	1
Gross, WL; Hellmich, B; Holl-Ulrich, K	1
Boyle, SN; Koleske, AJ	1
Shah, NP	1
Ali, Y; Egorin, MJ; Gharibo, MM; Gounder, MK; Lagattuta, TF; Lin, Y; Poplin, EA; Rubin, EH; Stein, MN	1
Faivre, S; Le Tourneau, C; Raymond, E	1
Biasco, G; Nannini, M; Pantaleo, MA; Saponara, M	1
Bonmort, M; Chaperot, L; Chaput, N; Flament, C; Ménard, C; Mignot, G; Plumas, J; Terme, M; Ullrich, E; Zitvogel, L	1
Grosdidier, A; Marull, M; Michielin, O; Rochat, B; von Grünigen, S; Zoete, V	1
Alberti, L; Arifi, S; Blay, JY; Cassier, P; Decouvelaere, AV; Dufresne, A; El Sayadi, H; Fayette, J; Méeus, P; Ranchère, D; Ray-Coquard, I; Tabone-Eglinger, S	1
Belani, CP; Doroshow, JH; Egorin, MJ; Grem, JL; Hamilton, A; Hayes, MJ; Ivy, SP; LoRusso, PA; Mulkerin, DL; Murgo, AJ; Peng, B; Potter, DM; Ramanathan, RK; Remick, SC; Takimoto, CH	1
Egorin, MJ; Flick, SM; Fu, P; Gibbons, J; Grem, JL; Ivy, SP; Lagattuta, TF; Lenz, HJ; LoRusso, PA; Mani, S; Mulkerin, DL; Murgo, AJ; Parise, RA; Pavlick, A; Ramanathan, RK; Remick, SC; Reynolds, S; Shibata, S; Takimoto, CH; Wang, Y	1
Beijnen, JH; Boss, DS; Olmos, RV; Schellens, JH; Sinaasappel, M	1
Giordano, S; Petrelli, A	1
Engelman, JA; Settleman, J	1
Bentley, B; Shao, R; Yan, W	1
Ohyashiki, JH; Ohyashiki, K; Tauchi, T	1
Fojo, T	1
Apperley, J; Corless, CL; Demetri, GD; Di Scala, L; Dirnhofer, S; Fletcher, JA; Harlow, A; Heinrich, MC; Herrmann, R; Joensuu, H; McArthur, AG; McKinley, A; Nikolova, Z; Seymour, J; Soulieres, D; Supple, SG; Town, A; van Oosterom, A	1
Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S	1
Lemonick, MD; Park, A	1
Stephenson, J	1
Adams, J; Elliott, PJ	1
Krystal, GW	1
Sachsenmaier, C	1
Goel, S; Mani, S; Perez-Soler, R	1
Buser, C; Sepp-Lorenzino, L; Takaki, T	1
Hochhaus, A	1
Hess, JL	1
Blanke, CD; Corless, CL; Druker, BJ; Heinrich, MC	1
Abbott, A	1
Hegedus, T; Kéri, G; Orfi, L; Sarkadi, B; Seprodi, A; Váradi, A	1

Reviews

134 review(s) available for imatinib mesylate and Benign Neoplasms

Article	Year
New strategies for targeting kinase networks in cancer. The Journal of biological chemistry, 2021, Volume: 297, Issue:4 Topics: Animals; Humans; Imatinib Mesylate; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Protein Kinases	2021
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. European journal of cancer (Oxford, England : 1990), 2021, Volume: 157 Topics: Consensus; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Imatinib Mesylate; Medical Oncology; Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Toxicology; Voluntary Health Agencies	2021
Myeloid Neoplasm with PCM1-PDGFRB Transcript Responded to Low-Dose Imatinib: One Case Report with Literature Review. Acta haematologica, 2022, Volume: 145, Issue:5 Topics: Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2022
Studying molecular signaling in major angiogenic diseases. Molecular and cellular biochemistry, 2022, Volume: 477, Issue:10 Topics: Angiogenesis Inhibitors; Bevacizumab; Cetuximab; Everolimus; Humans; Imatinib Mesylate; Neoplasms; Neovascularization, Pathologic; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2022
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. Internal and emergency medicine, 2021, Volume: 16, Issue:5 Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2021
Emerging Opportunities for Target Discovery in Rare Cancers. Cell chemical biology, 2017, Sep-21, Volume: 24, Issue:9 Topics: CRISPR-Cas Systems; Drug Discovery; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Precision Medicine; RNA Interference; Small Molecule Libraries	2017
Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs. The Journal of antibiotics, 2018, Volume: 71, Issue:8 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carbazoles; Drug Discovery; Furans; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Staurosporine	2018
Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes. Therapeutic drug monitoring, 2013, Volume: 35, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Population Surveillance; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome	2013
That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. British journal of pharmacology, 2013, Volume: 169, Issue:8 Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Cell Cycle; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Neoplasms; Piperazines; Proto-Oncogene Proteins B-raf; Pyrimidines; Sulfonamides; Vemurafenib	2013
[Anticancer drug adherence]. Bulletin du cancer, 2013, Volume: 100, Issue:5 Topics: Administration, Oral; Age Factors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Medication Adherence; Neoplasms; Physician's Role; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Socioeconomic Factors	2013
Comparison of different adjuvant therapies for 9 resectable cancer types. Postgraduate medicine, 2013, Volume: 125, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Imatinib Mesylate; Neoplasms; Numbers Needed To Treat; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2013
Imatinib mesylate. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2014, Volume: 201 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Signal Transduction	2014
Tyrosine kinase inhibitors: muco-cutaneous side effects at the microscope. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2014, Volume: 149, Issue:3 Topics: Antineoplastic Agents; Benzamides; Biopsy; Dasatinib; Exanthema; Humans; Imatinib Mesylate; Microscopy, Electron; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2014
Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey. Molecules (Basel, Switzerland), 2014, Sep-11, Volume: 19, Issue:9 Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cyclin-Dependent Kinases; Drug Design; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2014
Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Veterinary journal (London, England : 1997), 2015, Volume: 205, Issue:2 Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Imatinib Mesylate; Neoplasms; src-Family Kinases	2015
Chemotherapy- and irradiation-induced bone loss in adults with solid tumors. Current osteoporosis reports, 2015, Volume: 13, Issue:3 Topics: Adult; Antineoplastic Agents; Bone Resorption; Denosumab; Diphosphonates; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Methotrexate; Neoplasms; Radioisotopes; Radiotherapy; Taxoids	2015
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future oncology (London, England), 2015, Volume: 11, Issue:11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases	2015
[Kinase inhibitors and their resistance]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib	2015
[Pharmacokinetic issues on cancer pharmacotherapy]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Monitoring; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Piperazines; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Trastuzumab	2015
Analogs, formulations and derivatives of imatinib: a patent review. Expert opinion on therapeutic patents, 2015, Volume: 25, Issue:12 Topics: Animals; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Nanoparticles; Neoplasms; Patents as Topic	2015
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues. Regulatory toxicology and pharmacology : RTP, 2016, Volume: 77 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug and Narcotic Control; Drugs, Generic; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Neoplasms; Organ Specificity; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Signal Transduction; Sunitinib; Toxicity Tests	2016
MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia. Oncotarget, 2016, Jul-05, Volume: 7, Issue:27 Topics: Animals; Cell Survival; Chromosome Mapping; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; MicroRNAs; Mitogen-Activated Protein Kinases; Neoplasms; Rats; Signal Transduction	2016
Kinase Inhibitors in Multitargeted Cancer Therapy. Current medicinal chemistry, 2017, Volume: 24, Issue:16 Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib	2017
Anti-VEGF therapy: the search for clinical biomarkers. Expert review of molecular diagnostics, 2008, Volume: 8, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnostic Imaging; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Prognosis; Pyrimidines; Trastuzumab; Vascular Endothelial Growth Factor A	2008
Imaging in early phase childhood cancer trials. Pediatric radiology, 2009, Volume: 39 Suppl 1 Topics: Benzamides; Child; Clinical Trials as Topic; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Tomography, X-Ray Computed	2009
The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Current opinion in cell biology, 2009, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzamides; Drug Design; ErbB Receptors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Models, Molecular; Molecular Structure; Neoplasms; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyrimidines	2009
Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. Current cancer drug targets, 2009, Volume: 9, Issue:5 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Drug Tolerance; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Inactivation, Metabolic; Membrane Transport Proteins; Models, Biological; Neoplasms; Piperazines; Pyrimidines; Tissue Distribution; Xenobiotics	2009
Neurological adverse effects caused by cytotoxic and targeted therapies. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration	2009
Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models? European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:16 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Genetic Engineering; Humans; Imatinib Mesylate; Mice; Neoplasm Transplantation; Neoplasms; Piperazines; Pyrimidines; Transplantation, Heterologous; Trastuzumab	2009
Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties. Endocrine, metabolic & immune disorders drug targets, 2010, Volume: 10, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Dendritic Cells; Humans; Imatinib Mesylate; Immunomodulation; Interferons; Killer Cells, Natural; Mutation; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; T-Lymphocytes; T-Lymphocytes, Regulatory	2010
[Positron emission tomography and evaluation of response to targeted therapies]. Bulletin du cancer, 2009, Volume: 96, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Hypoxia; Cell Proliferation; Choline; ErbB Receptors; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lipid Metabolism; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Piperazines; Positron-Emission Tomography; Protein Biosynthesis; Protein Kinases; Pyrimidines; Radiopharmaceuticals; Receptors, Androgen; Receptors, Estrogen; TOR Serine-Threonine Kinases	2009
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2009
Imatinib mesylate. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 184 Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2010
Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clinical pharmacology and therapeutics, 2010, Volume: 87, Issue:5 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Therapy, Combination; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines	2010
Specificity in the interaction of natural products with their target proteins--a biochemical and structural insight. Mini reviews in medicinal chemistry, 2010, Volume: 10, Issue:6 Topics: Antineoplastic Agents; Benzamides; Biological Products; Cyclohexanes; Epoxy Compounds; Fatty Acids, Unsaturated; Flavonoids; Humans; Imatinib Mesylate; Macrolides; Neoplasms; Piperazines; Piperidines; Proteins; Pyrimidines; Sesquiterpenes	2010
Signal transduction therapy of cancer. Molecular aspects of medicine, 2010, Volume: 31, Issue:4 Topics: Animals; Antineoplastic Agents; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Piperazines; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction	2010
[Treatment with antiangiogenic drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Bevacizumab; Humans; Imatinib Mesylate; Indoles; Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A	2010
[Kinase inhibitors]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Benzamides; Bevacizumab; Biomarkers, Tumor; Drug Design; ErbB Receptors; Fusion Proteins, bcr-abl; Genes, ras; Humans; Imatinib Mesylate; Mutation; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphotransferases; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyrimidines; Rituximab; Signal Transduction	2010
Cytogenomics of cancers: from chromosome to sequence. Molecular oncology, 2010, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Base Sequence; Benzamides; Chromosome Aberrations; Chromosomes; Cytogenetics; Disease Progression; Genomics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2010
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:10 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine	2010
Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis. Future medicinal chemistry, 2011, Volume: 3, Issue:3 Topics: Benzamides; Dasatinib; Drug Discovery; Imatinib Mesylate; Inflammation; Models, Molecular; Molecular Conformation; Neoplasms; Patents as Topic; Phosphotransferases; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles	2011
Targeted therapy in pediatric and adolescent oncology. Cancer, 2011, May-15, Volume: 117, Issue:10 Suppl Topics: Adolescent; Angiogenesis Inhibitors; Benzamides; Child; fms-Like Tyrosine Kinase 3; Gangliosides; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Pharmacokinetics; Piperazines; Pyrimidines; Young Adult	2011
[Indications and current development of new targeted therapies in pediatric oncology]. Bulletin du cancer, 2011, Volume: 98, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases	2011
Targeted-therapy and imaging response: a new paradigm for clinical evaluation? Reviews on recent clinical trials, 2011, Volume: 6, Issue:3 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib	2011
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:2 Topics: Benzamides; Crizotinib; Fusion Proteins, bcr-abl; Gene Fusion; Humans; Imatinib Mesylate; MicroRNAs; Molecular Targeted Therapy; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Signal Transduction	2012
Pulmonary toxicities of tyrosine kinase inhibitors. Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:11 Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines	2011
Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klinische Padiatrie, 2012, Volume: 224, Issue:3 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Benzamides; Bevacizumab; Child; Delphi Technique; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Piperazines; Pyrimidines; Sirolimus; Young Adult	2012
[Protein tyrosine kinase inhibitors in cancer therapy]. Pathologie-biologie, 2012, Volume: 60, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction	2012
Evidence for therapeutic drug monitoring of targeted anticancer therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles	2012
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta ophthalmologica, 2013, Volume: 91, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab	2013
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annual review of pharmacology and toxicology, 2013, Volume: 53 Topics: Animals; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2013
Type II kinase inhibitors: an opportunity in cancer for rational design. Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:5 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2013
Monitoring after successful therapy for chronic myeloid leukemia. Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Benzamides; Cell Line, Tumor; Cytogenetics; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Medication Adherence; Neoplasms; Piperazines; Prevalence; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome	2012
Protein tyrosine kinase inhibitors: new treatment modalities? Current opinion in pharmacology, 2002, Volume: 2, Issue:4 Topics: Animals; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2002
[The principles of cancer treatment--changes in chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7 Topics: ADP Ribose Transferases; Animals; Antineoplastic Agents; Benzamides; Cisplatin; Drug Combinations; Fluorouracil; Genes, ras; Humans; Imatinib Mesylate; Insect Proteins; Lung Neoplasms; Mice; Neoplasms; Neoplastic Syndromes, Hereditary; Oxonic Acid; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Signal Transduction; Tegafur; Tumor Cells, Cultured	2002
[c-kit: an irresistible ascension from diagnostic marker to therapeutic]. Annales de pathologie, 2002, Volume: 22, Issue:3 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Enzyme Inhibitors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Mutation; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms	2002
Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction. Expert review of anticancer therapy, 2002, Volume: 2, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Gefitinib; Genetic Therapy; Genome, Human; Humans; Imatinib Mesylate; Neoplasms; Oncogenes; Piperazines; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab	2002
Clinical trial designs for targeted agents. Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5 Topics: Animals; Antineoplastic Agents; Benzamides; Biomarkers; Biphenyl Compounds; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Imatinib Mesylate; Matrix Metalloproteinase Inhibitors; Mice; Neoplasm Proteins; Neoplasms; Organic Chemicals; Outcome Assessment, Health Care; Patient Selection; Phenylbutyrates; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Rats	2002
Imatinib: a selective tyrosine kinase inhibitor. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 5 Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Cell Communication; Drug Design; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasm Proteins; Neoplasms; Oncogene Proteins; Piperazines; Protein Binding; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Structure-Activity Relationship	2002
Targeting oncogene dependence and resistance. Cancer cell, 2003, Volume: 3, Issue:5 Topics: Alleles; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasms; Oncogenes; Piperazines; Pyrimidines	2003
Molecular-genetic imaging: current and future perspectives. The Journal of clinical investigation, 2003, Volume: 111, Issue:11 Topics: Animals; Benzamides; Diagnostic Imaging; Gene Expression Regulation; Genes, Reporter; Genetic Techniques; Humans; Imatinib Mesylate; Models, Biological; Neoplasms; Piperazines; Pyrimidines; Time Factors; Tomography, Emission-Computed; Tumor Suppressor Protein p53	2003
Protein kinase inhibitors as a therapeutic modality. Accounts of chemical research, 2003, Volume: 36, Issue:6 Topics: Antineoplastic Agents; Benzamides; Drug Design; Enzyme Inhibitors; Humans; Imatinib Mesylate; Molecular Mimicry; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Signal Transduction	2003
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. Advances in experimental medicine and biology, 2003, Volume: 532 Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Ligands; Male; Models, Biological; Mutation; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2003
Beyond Herceptin and Gleevec. Current opinion in chemical biology, 2003, Volume: 7, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cell Cycle; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Neoplasms; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Trastuzumab	2003
Targeted therapies for the treatment of cancer. American journal of surgery, 2003, Volume: 186, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Lymphoma, B-Cell; Male; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Trastuzumab	2003
An overview of targeted treatments in cancer. Clinical therapeutics, 2003, Volume: 25, Issue:8 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Cancer Vaccines; Drug Delivery Systems; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Tretinoin	2003
[Current screening for molecular target therapy of cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib	2003
Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncology research, 2004, Volume: 14, Issue:4-5 Topics: Angiogenesis Inhibitors; Benzamides; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer cell, 2004, Volume: 5, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cardiomyoplasty; Colorectal Neoplasms; Cyclooxygenase 2; Disease Models, Animal; ErbB Receptors; Gastrointestinal Diseases; Genes, abl; Genetic Engineering; Humans; Imatinib Mesylate; Isoenzymes; Membrane Proteins; Mice; Mice, Transgenic; Neoplasms; Piperazines; Prostaglandin-Endoperoxide Synthases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Transforming Growth Factor beta; Skin Abnormalities; Trastuzumab; Vascular Endothelial Growth Factor A	2004
Lessons learned from the development of imatinib. Leukemia research, 2004, Volume: 28 Suppl 1 Topics: Benzamides; Drug Design; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship	2004
Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surgery today, 2004, Volume: 34, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Molecular Biology; Neoplasms; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2004
Cancer stem cells: are we missing the target? Journal of the National Cancer Institute, 2004, Apr-21, Volume: 96, Issue:8 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Neoplastic Stem Cells; Piperazines; Pyrimidines; Survival	2004
Role of KIT and platelet-derived growth factor receptors as oncoproteins. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stem Cell Factor	2004
Increasing tumor uptake of anticancer drugs with imatinib. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Enzyme Inhibitors; Extracellular Fluid; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2004
Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. International journal of clinical practice, 2004, Volume: 58, Issue:5 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Pilot Projects; Piperazines; Prognosis; Pyrimidines	2004
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine & growth factor reviews, 2004, Volume: 15, Issue:4 Topics: Animals; Benzamides; Biological Transport; DNA Mutational Analysis; Fibroblasts; Humans; Imatinib Mesylate; Models, Biological; Mutation; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stromal Cells	2004
Tyrosine kinase inhibitors in cancer therapy. Clinical biochemistry, 2004, Volume: 37, Issue:7 Topics: Benzamides; Clinical Trials as Topic; Forecasting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
[The mechanisms of the resistance to molecular targeting agents]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Drug Delivery Systems; Drug Resistance, Neoplasm; Gefitinib; Humans; Imatinib Mesylate; In Vitro Techniques; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Trastuzumab	2004
Imatinib as a paradigm of targeted therapies. Advances in cancer research, 2004, Volume: 91 Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Neoplasm Proteins; Neoplasms; Oncogenes; Patient Selection; Piperazines; Protein Conformation; Protein-Tyrosine Kinases; Pyrimidines	2004
Kinase inhibitors translate lab discoveries into exciting new cures for cancers. Indian journal of pediatrics, 2004, Volume: 71, Issue:8 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
[Targeted anticancer drugs and their development]. Duodecim; laaketieteellinen aikakauskirja, 2004, Volume: 120, Issue:19 Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Drug Delivery Systems; Female; Humans; Imatinib Mesylate; Male; Neoplasms; Neovascularization, Pathologic; Piperazines; Prognosis; Pyrimidines; Risk Factors; Treatment Outcome	2004
Oncogenic derivatives of platelet-derived growth factor receptors. Cellular and molecular life sciences : CMLS, 2004, Volume: 61, Issue:23 Topics: Benzamides; Gene Deletion; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Ligands; Models, Biological; Models, Genetic; Mutation; Neoplasms; Piperazines; Point Mutation; Protein Isoforms; Protein Structure, Tertiary; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Translocation, Genetic	2004
Kit as a human oncogenic tyrosine kinase. Cellular and molecular life sciences : CMLS, 2004, Volume: 61, Issue:23 Topics: Animals; Benzamides; Dimerization; Gastrointestinal Stromal Tumors; Homozygote; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Mice; Models, Biological; Mutation; Neoplasms; Neoplasms, Germ Cell and Embryonal; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Signal Transduction; Structure-Activity Relationship	2004
Reversing resistance to targeted therapy. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Male; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Risk Assessment; Sensitivity and Specificity; Trastuzumab	2004
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell cycle (Georgetown, Tex.), 2005, Volume: 4, Issue:3 Topics: Animals; Benzamides; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Cloning, Molecular; DNA, Complementary; Drug Resistance; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genetic Techniques; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Mutagenesis; Mutation; Neoplasms; Piperazines; Protein Binding; Protein-Tyrosine Kinases; Pyrimidines	2005
[Molecular target therapy for malignant tumors]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2005, Feb-20, Volume: 94 Suppl Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; ErbB Receptors; Fusion Proteins, bcr-abl; Gefitinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Trastuzumab; Tretinoin	2005
[Optimizing current drugs]. Annales pharmaceutiques francaises, 2005, Volume: 63, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Camptothecin; History, 20th Century; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines	2005
Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice, 2005, Volume: 5, Issue:2 Topics: Animals; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2005
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clinical pharmacokinetics, 2005, Volume: 44, Issue:4 Topics: Antineoplastic Agents; Benzamides; Biotransformation; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Isoenzymes; Neoplasms; Paclitaxel; Piperazines; Polymorphism, Genetic; Pyrimidines; Tamoxifen	2005
[Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals]. Deutsche medizinische Wochenschrift (1946), 2005, May-27, Volume: 130, Issue:21 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Dimerization; Enzyme Activation; Growth Substances; Humans; Imatinib Mesylate; Neoplasms; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction	2005
[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives]. Deutsche medizinische Wochenschrift (1946), 2005, Jun-10, Volume: 130, Issue:23 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, abl; Humans; Imatinib Mesylate; Neoplasms; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A	2005
Cutaneous side-effects of kinase inhibitors and blocking antibodies. The Lancet. Oncology, 2005, Volume: 6, Issue:7 Topics: Antibodies, Blocking; Antineoplastic Agents; Benzamides; Benzenesulfonates; ErbB Receptors; Hair Diseases; Humans; Imatinib Mesylate; Nail Diseases; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Skin Diseases; Sorafenib	2005
Tyrosine kinases as targets for cancer therapy. The New England journal of medicine, 2005, Jul-14, Volume: 353, Issue:2 Topics: Antibodies, Monoclonal; Benzamides; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases	2005
[Current progress in therapy of malignant diseases]. Deutsche medizinische Wochenschrift (1946), 2005, Aug-05, Volume: 130, Issue:31-32 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Neoplasms; Piperazines; Pyrimidines	2005
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice, 2005, Volume: 5, Issue:5 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2005
Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. Biochemical and biophysical research communications, 2005, Dec-23, Volume: 338, Issue:3 Topics: Animals; Benzamides; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction	2005
[Genetic alterations and chemoresistance]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:12 Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzamides; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines; Thymidylate Synthase; Xeroderma Pigmentosum Group D Protein	2005
[Targeted therapies in pediatric oncology: a new therapeutic approach?]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2006, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Benzamides; Child; ErbB Receptors; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor Protein-Tyrosine Kinases	2006
[Antineoplastic agents targeting tyrosine kinases]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Nov-17, Volume: 125, Issue:22 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab	2005
[Cancer initiation as mini-evolution]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2005, Volume: 50, Issue:15 Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Chromosomal Instability; Computational Biology; Epithelial Cells; Evolution, Molecular; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Mutation; Neoplasms; Neoplastic Stem Cells; Piperazines; Pyrimidines	2005
[Gene expression profiling for prediction of response to chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:1 Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Targeting; Genome, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines	2006
[Problems in the current target therapy of malignancies]. Voprosy onkologii, 2005, Volume: 51, Issue:5 Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab	2005
Methodological aspects of current problems in target-based anticancer drug development. International journal of clinical oncology, 2006, Volume: 11, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Design; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Research Design; Trastuzumab	2006
[Requirements for the development of molecularly defined targeted therapy in oncology]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Bevacizumab; Biomedical Research; Biotechnology; Breast Neoplasms; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computational Biology; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Industry; Female; Gemcitabine; Genome, Human; Humans; Imatinib Mesylate; Medical Oncology; Molecular Biology; Multicenter Studies as Topic; Neoplasms; Phenotype; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Trastuzumab; Treatment Outcome	2006
[Targeted therapies of cancer: not lost in translation]. Bulletin du cancer, 2006, Volume: 93, Issue:8 Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Proteins; Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2006
Mathematical models of targeted cancer therapy. British journal of cancer, 2006, Nov-06, Volume: 95, Issue:9 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Growth Factor; Treatment Outcome	2006
Protein kinases as drug targets in cancer. Current cancer drug targets, 2006, Volume: 6, Issue:7 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzenesulfonates; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Trastuzumab	2006
[Molecular targeted therapy]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2006, Volume: 77, Issue:12 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Cancer Vaccines; Cell Survival; Clinical Trials as Topic; Drug Delivery Systems; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Trastuzumab	2006
Protein kinase inhibitors. Folia biologica, 2006, Volume: 52, Issue:4 Topics: Animals; Benzamides; Cyclin-Dependent Kinases; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2006
Why is cancer drug discovery so difficult? Nature reviews. Drug discovery, 2007, Volume: 6, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quantitative Trait Loci	2007
[Current events about echography in 2006: position of the ultrasound functional imaging for the early evaluation of targeted therapeutics]. Bulletin du cancer, 2006, Volume: 93, Issue:12 Topics: Antineoplastic Agents; Benzamides; Contrast Media; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Neoplasms; Microcirculation; Neoplasms; Neovascularization, Pathologic; Phospholipids; Piperazines; Polysaccharides; Pyrimidines; Sulfur Hexafluoride; Treatment Outcome; Ultrasonography	2006
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clinical lymphoma & myeloma, 2007, Volume: 7 Suppl 3 Topics: Benzamides; Clinical Trials as Topic; Follow-Up Studies; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Time Factors; United States; United States Food and Drug Administration	2007
PDGF receptors as targets in tumor treatment. Advances in cancer research, 2007, Volume: 97 Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Extracellular Fluid; Fibroblasts; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pressure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Translocation, Genetic	2007
Targeted cancer therapy: promise and reality. Advances in cancer research, 2007, Volume: 97 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Drug Screening Assays, Antitumor; ErbB Receptors; Forecasting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction	2007
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:2 Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous	2007
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer control : journal of the Moffitt Cancer Center, 2007, Volume: 14, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A	2007
[Hypereosinophilic syndrome--recent developments in diagnosis and treatment]. Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:37 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Hypersensitivity; Imatinib Mesylate; Immunosuppressive Agents; Interferon-alpha; Lung Diseases; Neoplasms; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tumor Necrosis Factor-alpha; Vasculitis	2007
Dissecting kinase signaling pathways. Drug discovery today, 2007, Volume: 12, Issue:17-18 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab	2007
New developments in multitargeted therapy for patients with solid tumours. Cancer treatment reviews, 2008, Volume: 34, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles	2008
Targeted therapies in solid tumours: results and promises. Minerva medica, 2007, Volume: 98, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Neoplasms; Piperazines; Pyrimidines; Trastuzumab	2007
Dendritic cells and innate defense against tumor cells. Cytokine & growth factor reviews, 2008, Volume: 19, Issue:1 Topics: Apoptosis; Benzamides; Biomarkers, Tumor; Cancer Vaccines; CpG Islands; Cytokines; Dendritic Cells; Fas Ligand Protein; Granulocyte-Macrophage Colony-Stimulating Factor; HMGB1 Protein; Humans; Imatinib Mesylate; Immunity, Innate; Interferon Type I; Interferon-gamma; Interferons; Interleukin-15; Killer Cells, Natural; Neoplasms; Oligodeoxyribonucleotides; Piperazines; Pyrimidines; Receptor Cross-Talk; T-Lymphocytes, Helper-Inducer; Uric Acid	2008
[Imatinib and solid tumours]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasms; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	2008
Application of PET/CT in the development of novel anticancer drugs. The oncologist, 2008, Volume: 13, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Neoplasm Staging; Neoplasms; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed	2008
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Current medicinal chemistry, 2008, Volume: 15, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab	2008
Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current opinion in genetics & development, 2008, Volume: 18, Issue:1 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2008
Commentary: Novel therapies for cancer: why dirty might be better. The oncologist, 2008, Volume: 13, Issue:3 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2	2008
New agents in cancer clinical trials. Oncogene, 2000, Dec-27, Volume: 19, Issue:56 Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat	2000
Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2001, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gene Amplification; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2001
Targeting protein kinases for tumor therapy. Onkologie, 2001, Volume: 24, Issue:4 Topics: Antineoplastic Agents; Benzamides; Cell Division; Cell Survival; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Receptor Protein-Tyrosine Kinases	2001
Tyrosine kinase inhibitors: a clinical perspective. Current oncology reports, 2002, Volume: 4, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; Molecular Structure; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Trastuzumab	2002
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]. Deutsche medizinische Wochenschrift (1946), 2002, Mar-01, Volume: 127, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytogenetics; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Mastocytosis; Multicenter Studies as Topic; Mutation; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors	2002
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6 Topics: Angiogenesis Inhibitors; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasms; Oxindoles; Piperazines; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles	2002
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochimica et biophysica acta, 2002, Jul-18, Volume: 1587, Issue:2-3 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; In Vitro Techniques; Multidrug Resistance-Associated Proteins; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins; Tumor Cells, Cultured	2002

Trials

13 trial(s) available for imatinib mesylate and Benign Neoplasms

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. Journal for immunotherapy of cancer, 2017, Volume: 5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imatinib Mesylate; Ipilimumab; Male; Middle Aged; Neoplasms; Young Adult	2017
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. British journal of cancer, 2013, Nov-12, Volume: 109, Issue:10 Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chordoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasms; Piperazines; Pyrimidines; Skin Neoplasms	2013
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer research, 2010, Volume: 30, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Capecitabine; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Neovascularization, Physiologic; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrimidines; Skin	2010
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Michigan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; New Jersey; Perfusion Imaging; Piperazines; Pyrimidines; Taxoids; Time Factors; Treatment Outcome	2012
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer research, 2011, Feb-01, Volume: 71, Issue:3 Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Differentiation; Cyclophosphamide; Female; Humans; Imatinib Mesylate; Interleukin-2; Lymphocyte Subsets; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Middle Aged; Neoplasms; Piperazines; Pyrimidines; T-Lymphocytes, Regulatory; Th17 Cells	2011
A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies. Cancer investigation, 2011, Volume: 29, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Risk Assessment; Tennessee; Time Factors; Treatment Outcome; Young Adult	2011
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Severity of Illness Index; Treatment Outcome	2012
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatric blood & cancer, 2008, Volume: 50, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial	2008
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-01, Volume: 13, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperazines; Pyrimidines; Treatment Outcome	2007
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bilirubin; Female; Gastrointestinal Diseases; Humans; Imatinib Mesylate; Liver Diseases; Liver Function Tests; Male; Middle Aged; Neoplasms; Piperazines; Pyrimidines	2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Biological Availability; Creatinine; Female; Half-Life; Humans; Hypophosphatemia; Imatinib Mesylate; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Neoplasms; Piperazines; Pyrimidines	2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, May-01, Volume: 14, Issue:9 Topics: Antineoplastic Agents; Benzamides; Hematologic Neoplasms; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Mutation; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2008

Other Studies

160 other study(ies) available for imatinib mesylate and Benign Neoplasms

Article	Year
Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents. European journal of medicinal chemistry, 2011, Volume: 46, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclin D1; Down-Regulation; G1 Phase; Humans; Neoplasms; NF-kappa B; Pyrimidines; Sulfonamides	2011
Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression. European journal of medicinal chemistry, 2020, Dec-01, Volume: 207 Topics: A549 Cells; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Design; Humans; Imidazoles; Neoplasms; Nylons; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Pyrroles	2020
[Successful treatment with imatinib for a patient with myeloid neoplasms with eosinophilia and abnormalities of PDGFRB due to t (5;14)(q33;q22)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2021, Volume: 62, Issue:11 Topics: Eosinophilia; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Neoplasms; Receptor, Platelet-Derived Growth Factor beta	2021
New Imatinib Derivatives with Antiproliferative Activity against A549 and K562 Cancer Cells. Molecules (Basel, Switzerland), 2022, Jan-24, Volume: 27, Issue:3 Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; K562 Cells; Neoplasms; Protein Kinase Inhibitors	2022
Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein. Fundamental & clinical pharmacology, 2022, Volume: 36, Issue:5 Topics: Administration, Oral; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Axitinib; Crizotinib; Dabigatran; Drug Interactions; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Rivaroxaban	2022
Pharmacological PDGFRβ inhibitors imatinib and sunitinib cause human brain pericyte death in vitro. Toxicology and applied pharmacology, 2022, 06-01, Volume: 444 Topics: Brain; Humans; Imatinib Mesylate; Neoplasms; Pericytes; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Sunitinib	2022
Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers. Scientific reports, 2022, 06-20, Volume: 12, Issue:1 Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Neoplasms; Pharmacovigilance; Quality of Life	2022
Imatinib responsive erythrocytosis in a patient with FIP1L1::PDGFRA rearranged myeloid neoplasm with hypereosinophilia - Another manifestation of a stem cell neoplasm. Leukemia research, 2022, Volume: 121 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Polycythemia; Stem Cells	2022
Pseudo-Gaucher cells in a myeloid neoplasm with PDGFRB rearrangement: imitating the imitator. Blood, 2022, 08-11, Volume: 140, Issue:6 Topics: Gene Rearrangement; Humans; Imatinib Mesylate; Myeloproliferative Disorders; Neoplasms; Receptor, Platelet-Derived Growth Factor beta	2022
A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement. Blood, 2023, 05-18, Volume: 141, Issue:20 Topics: Eosinophilia; Humans; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2023
False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay. Acta haematologica, 2023, Volume: 146, Issue:4 Topics: Benzamides; Delayed Diagnosis; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Piperazines; Pyrimidines	2023
Screening and Analysis of Possible Drugs Binding to PDGFRα: A Molecular Modeling Study. International journal of molecular sciences, 2023, Jun-01, Volume: 24, Issue:11 Topics: Humans; Imatinib Mesylate; Models, Molecular; Molecular Docking Simulation; Neoplasms; Quantitative Structure-Activity Relationship; Receptor, Platelet-Derived Growth Factor alpha	2023
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood advances, 2020, 02-11, Volume: 4, Issue:3 Topics: DNA Helicases; Eosinophilia; Humans; Imatinib Mesylate; Male; Neoplasms; Poly-ADP-Ribose Binding Proteins; Receptor, Platelet-Derived Growth Factor beta; RNA Helicases; RNA Recognition Motif Proteins; Young Adult	2020
Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm. Leukemia & lymphoma, 2020, Volume: 61, Issue:9 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukoencephalopathy, Progressive Multifocal; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2020
Myeloid neoplasm with the abnormality of PDGFRB gene secondary interstitial pneumonia: A case report. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2020, Mar-28, Volume: 45, Issue:3 Topics: Aged; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Male; Myeloproliferative Disorders; Neoplasms; Receptor, Platelet-Derived Growth Factor beta	2020
Mathematical Oncology Comes to the Clinic: A Data-Driven Treatment for Financial Toxicity? Cancer research, 2020, 06-01, Volume: 80, Issue:11 Topics: Humans; Imatinib Mesylate; Medical Oncology; Neoplasms	2020
Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proceedings of the National Academy of Sciences of the United States of America, 2020, 08-11, Volume: 117, Issue:32 Topics: Adenosine Triphosphate; Amino Acid Sequence; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplasms; Oncogene Proteins v-abl	2020
Identification of benzimidazole containing 4 Journal of receptor and signal transduction research, 2021, Volume: 41, Issue:2 Topics: Adenosine Triphosphate; Allosteric Site; Benzimidazoles; Computer Simulation; Drug Design; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Molecular Docking Simulation; Molecular Structure; Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Structure-Activity Relationship	2021
Benzylidene thiazolidinediones: Synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib. Bioorganic & medicinal chemistry letters, 2020, 12-01, Volume: 30, Issue:23 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylidene Compounds; Cell Line, Tumor; Cell Proliferation; Female; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Male; Mice, Nude; Molecular Structure; Neoplasms; Structure-Activity Relationship; Thiazolidinediones; Xenograft Model Antitumor Assays	2020
A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. Journal of the National Comprehensive Cancer Network : JNCCN, 2020, Volume: 18, Issue:10 Topics: Eosinophilia; Humans; Imatinib Mesylate; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2020
Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report. Oral surgery, oral medicine, oral pathology and oral radiology, 2021, Volume: 131, Issue:5 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Imatinib Mesylate; Neoplasms; Osteonecrosis	2021
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. British journal of clinical pharmacology, 2017, Volume: 83, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult	2017
Mesoporous nano-bioglass designed for the release of imatinib and in vitro inhibitory effects on cancer cells. Materials science & engineering. C, Materials for biological applications, 2017, Aug-01, Volume: 77 Topics: Biocompatible Materials; Ceramics; Glass; Humans; Imatinib Mesylate; Neoplasms; Porosity; X-Ray Diffraction	2017
QnAs with Tony Hunter and James Allison. Proceedings of the National Academy of Sciences of the United States of America, 2017, 06-27, Volume: 114, Issue:26 Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Neoplasms	2017
Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clinical pharmacokinetics, 2018, Volume: 57, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Bayes Theorem; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Imatinib Mesylate; Medication Adherence; Models, Biological; Molecular Targeted Therapy; Neoplasms	2018
Amplification of F-Actin Disassembly and Cellular Repulsion by Growth Factor Signaling. Developmental cell, 2017, 07-24, Volume: 42, Issue:2 Topics: Actins; Animals; Axon Guidance; Biocatalysis; Biomechanical Phenomena; Cell Adhesion Molecules; Cell Proliferation; Drosophila melanogaster; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Mice, Nude; Mixed Function Oxygenases; Models, Biological; Neoplasms; Nerve Tissue Proteins; Oxidation-Reduction; Phosphorylation; Protein Binding; Protein Domains; Proto-Oncogene Proteins c-abl; Semaphorins; Signal Transduction	2017
[Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs]. Bulletin du cancer, 2017, Volume: 104, Issue:9 Topics: Antineoplastic Agents; Bayes Theorem; Bevacizumab; Colorectal Neoplasms; Drug Monitoring; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Liver; Neoplasms; Phenylurea Compounds; Pyridines	2017
Kinase Inhibitors: The Reality Behind the Success. Clinical pharmacology and therapeutics, 2017, Volume: 102, Issue:5 Topics: Animals; Carcinogenesis; Humans; Imatinib Mesylate; Medical Oncology; Neoplasms; Protein Kinase Inhibitors	2017
Precision Medicine: Where have we reached and where are we headed? Sultan Qaboos University medical journal, 2017, Volume: 17, Issue:3 Topics: Antineoplastic Agents; Evidence-Based Medicine; Forecasting; Humans; Imatinib Mesylate; Neoplasms; Precision Medicine; Rituximab; Trastuzumab	2017
Pleural and pericardial effusions in patient on tyrosine kinase inhibitor. Journal of clinical anesthesia, 2018, Volume: 45 Topics: Aged; Female; Humans; Imatinib Mesylate; Neoplasms; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2018
Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society, 2018, 07-10, Volume: 281 Topics: Animals; Antineoplastic Agents; Apoptosis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Survival; CTLA-4 Antigen; Humans; Imatinib Mesylate; Immunosuppression Therapy; Immunotherapy; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Peptides; Phosphorylation; STAT3 Transcription Factor; STAT5 Transcription Factor; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Microenvironment	2018
Design, synthesis and 3D QSAR based pharmacophore study of novel imatinib analogs as antitumor-apoptotic agents. Future medicinal chemistry, 2018, 06-01, Volume: 10, Issue:12 Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Models, Molecular; Neoplasms; Quantitative Structure-Activity Relationship	2018
Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:6 Topics: Adult; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Prescriptions; Female; Health Expenditures; Humans; Imatinib Mesylate; Lenalidomide; Male; Middle Aged; Neoplasms; Prescription Fees; Retrospective Studies; Survival Analysis; Thalidomide; United States; Young Adult	2018
A pharmacovigilance system for treatment access and medical donation programs: The Max Foundation experience. Globalization and health, 2018, 07-27, Volume: 14, Issue:1 Topics: Antineoplastic Agents; Developing Countries; Drug Industry; Health Services Accessibility; Humans; Imatinib Mesylate; Neoplasms; Pharmacovigilance; Program Evaluation	2018
Embracing the complexity in cancer therapy. The Lancet. Haematology, 2018, Volume: 5, Issue:11 Topics: Animals; Antibodies, Blocking; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Humans; Imatinib Mesylate; Immunotherapy; Neoplasms; Nobel Prize; Physiology; Programmed Cell Death 1 Receptor	2018
Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. BioMed research international, 2019, Volume: 2019 Topics: Animals; Anthracenes; Anticarcinogenic Agents; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Neoplasms; Organ Specificity; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Tumor Suppressor Protein p53	2019
The Time Has Come! Journal of the National Comprehensive Cancer Network : JNCCN, 2019, 04-01, Volume: 17, Issue:4 Topics: Humans; Imatinib Mesylate; Neoplasms	2019
"Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay." Is dPCR the key? European journal of haematology, 2019, Volume: 103, Issue:3 Topics: Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasms; Real-Time Polymerase Chain Reaction	2019
Factors Influencing Imatinib-Induced Hepatotoxicity. Cancer research and treatment, 2020, Volume: 52, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemical and Drug Induced Liver Injury; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Odds Ratio; Prognosis; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Treatment Outcome	2020
Evolutionary variation and adaptation in a conserved protein kinase allosteric network: implications for inhibitor design. Biochimica et biophysica acta, 2013, Volume: 1834, Issue:7 Topics: Allosteric Regulation; Allosteric Site; Archaea; Bacteria; Benzamides; Biocatalysis; Drug Design; Eukaryotic Cells; Evolution, Molecular; Genetic Variation; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Imatinib Mesylate; Models, Molecular; Neoplasms; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Protein Structure, Secondary; Protein Structure, Tertiary; Proto-Oncogene Proteins c-pim-1; Pyrimidines	2013
India's patent case victory rattles Big Pharma. Lancet (London, England), 2013, Apr-13, Volume: 381, Issue:9874 Topics: Antineoplastic Agents; Benzamides; Drug Industry; Drugs, Generic; Humans; Imatinib Mesylate; India; Legislation, Drug; Neoplasms; Patents as Topic; Piperazines; Pyrimidines	2013
Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases. Journal of the American Chemical Society, 2013, Oct-02, Volume: 135, Issue:39 Topics: Antineoplastic Agents; Benzamides; Binding Sites; CSK Tyrosine-Protein Kinase; Humans; Imatinib Mesylate; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Molecular Dynamics Simulation; Neoplasms; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; src-Family Kinases; Thermodynamics	2013
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Therapeutic drug monitoring, 2014, Volume: 36, Issue:3 Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry	2014
Janet Rowley (1925-2013). Nature, 2014, Jan-23, Volume: 505, Issue:7484 Topics: Benzamides; Genetics, Medical; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms; Piperazines; Pyrimidines; Translocation, Genetic; United States	2014
Therapy: This time it's personal. Nature, 2014, May-29, Volume: 509, Issue:7502 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biological Evolution; Biopsy; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Delivery Systems; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Genetics, Medical; Genomics; Humans; Imatinib Mesylate; Immunotherapy; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Nanoparticles; Neoplasms; Pharmacogenetics; Piperazines; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyrimidines; RNA Interference; RNA, Small Interfering; Sulfonamides; Time Factors; Transcriptome; Vemurafenib	2014
Biology: Three known unknowns. Nature, 2014, May-29, Volume: 509, Issue:7502 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biological Evolution; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Immunity; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Metastasis; Neoplasms; Piperazines; Pyrimidines; Tumor Microenvironment	2014
This time it's personal. Scientific American, 2014, Volume: 311, Issue:1 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Precision Medicine; Pyrimidines; Transcriptome	2014
Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone. PloS one, 2014, Volume: 9, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspase 7; Cell Line, Tumor; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mitoxantrone; Neoplasms; Oncogene Proteins, Viral; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; RNA Interference; S Phase Cell Cycle Checkpoints; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53	2014
Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. Nature structural & molecular biology, 2014, Volume: 21, Issue:10 Topics: Antineoplastic Agents; Benzamides; Cell Line; Humans; Imatinib Mesylate; Kinetics; Neoplasms; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Thermodynamics	2014
Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:1 Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Case-Control Studies; Cytogenetics; DNA-Binding Proteins; Female; Gene Expression Regulation, Leukemic; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms; Polymorphism, Restriction Fragment Length; Prevalence; Treatment Outcome; X-ray Repair Cross Complementing Protein 1	2016
Sos1 Regulates Macrophage Podosome Assembly and Macrophage Invasive Capacity. Journal of immunology (Baltimore, Md. : 1950), 2015, Nov-15, Volume: 195, Issue:10 Topics: Animals; Cell Movement; Chlorocebus aethiops; COS Cells; Humans; Imatinib Mesylate; Macrophages; Mice; Neoplasm Invasiveness; Neoplasms; Phosphorylation; Podosomes; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; rac GTP-Binding Proteins; SOS1 Protein; src-Family Kinases	2015
Reversing cancer stemness. Aging, 2015, Volume: 7, Issue:11 Topics: Epithelial-Mesenchymal Transition; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Receptor, Platelet-Derived Growth Factor alpha	2015
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ open, 2016, Jan-27, Volume: 6, Issue:1 Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib	2016
Nanoporous capsules of block co-polymers of [(MeO-PEG-NH)-b-(L-GluA)]-PCL for the controlled release of anticancer drugs for therapeutic applications. Nanotechnology, 2016, Mar-29, Volume: 27, Issue:12 Topics: Antineoplastic Agents; Capsules; Cell Survival; Delayed-Action Preparations; Doxorubicin; Glucose Transporter Type 1; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Nanopores; Neoplasms; Particle Size; Polyesters; Polymers	2016
Pathological fracture due to lytic lesion caused by a myeloid neoplasm with FIP1L1-PDGFRA. British journal of haematology, 2016, Volume: 174, Issue:5 Topics: Adult; Eosinophilia; Femur Neck; Fractures, Bone; Humans; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2016
Theory and practice of clinical pharmacodynamics in oncology drug development. Seminars in oncology, 2016, Volume: 43, Issue:4 Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Chemistry Techniques, Analytical; Drug Design; Drug Discovery; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Reproducibility of Results; Specimen Handling	2016
Disease progression in some cancers may be due to low blood levels of targeted therapies. Journal of the National Cancer Institute, 2008, Jul-02, Volume: 100, Issue:13 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Biological Availability; Dasatinib; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2008
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. Cancer research, 2008, Jul-15, Volume: 68, Issue:14 Topics: Adolescent; Adult; Age Factors; Aged; Animals; Benzamides; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myeloid, Acute; Medical Oncology; Mice; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transcription Factors	2008
[Pharmazie in unserer Zeit 5/2008]. Pharmazie in unserer Zeit, 2008, Volume: 37, Issue:5 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tyrosine 3-Monooxygenase	2008
Inhibition of imatinib transport by uremic toxins during renal failure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-01, Volume: 26, Issue:25 Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzamides; Biological Availability; Biological Transport; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Liver Failure; Neoplasms; Organic Anion Transporters; Paclitaxel; Piperazines; Pyrimidines; Xenopus laevis	2008
[Cardiac toxicity and edema]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Edema, Cardiac; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Prodrugs; Pyrimidines; Risk Factors; Trastuzumab	2008
[Practical approach to hypereosinophilia]. Revue medicale de Bruxelles, 2008, Volume: 29, Issue:4 Topics: Benzamides; Eosinophils; Food Hypersensitivity; Glucocorticoids; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Mutation; Neoplasms; Parasitic Diseases; Piperazines; Prednisone; Protein-Tyrosine Kinases; Pulmonary Eosinophilia; Pyrimidines	2008
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer science, 2009, Volume: 100, Issue:1 Topics: Animals; Benzamides; Benzenesulfonates; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2009
Catastrophic tumour lysis syndrome following single dose of imatinib. European journal of haematology, 2009, Volume: 82, Issue:3 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Piperazines; Pyrimidines; Tumor Lysis Syndrome	2009
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Molecular cancer therapeutics, 2009, Volume: 8, Issue:1 Topics: Animals; Benzamides; Cell Line, Tumor; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neoplasms; Piperazines; Pyrimidines; Rad51 Recombinase; Radiation Tolerance; Recombination, Genetic; Xenograft Model Antitumor Assays	2009
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:13 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Drug Administration Schedule; Exons; Female; Humans; Imatinib Mesylate; Male; Neoplasms; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome; Young Adult	2009
A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates. Journal of biopharmaceutical statistics, 2009, Volume: 19, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzamides; Clinical Trials, Phase I as Topic; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Logistic Models; Maximum Tolerated Dose; Multivariate Analysis; Neoplasms; Piperazines; Probability; Pyrimidines	2009
Promises and pitfalls of oral cancer chemotherapy. Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:2 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Drug Monitoring; Imatinib Mesylate; Medication Adherence; Neoplasms; Patient Education as Topic; Physician-Patient Relations; Piperazines; Pyrimidines	2009
The therapeutic benefits of heme oxygenase (HO-1) inhibition in the management of systemic malignancies besides hepatocellular carcinomas. International journal of cancer, 2009, Aug-01, Volume: 125, Issue:3 Topics: Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Enzyme Inhibitors; Heme Oxygenase-1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Nasopharyngeal Neoplasms; Neoplasms; Piperazines; Protoporphyrins; Pyrimidines; Sarcoma, Kaposi	2009
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-01, Volume: 15, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Utilization Review; Fractures, Bone; Heart Failure; Humans; Imatinib Mesylate; Infections; Neoplasms; Piperazines; Product Surveillance, Postmarketing; Professional Staff Committees; Pulmonary Edema; Pyrimidines; Time Factors	2009
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jul-15, Volume: 877, Issue:22 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles	2009
Perspectives on the development of imatinib and the future of cancer research. Nature medicine, 2009, Volume: 15, Issue:10 Topics: Awards and Prizes; Benzamides; Clinical Trials as Topic; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Research; United States	2009
Attacking cancer at its foundation. Nature medicine, 2009, Volume: 15, Issue:10 Topics: Academic Medical Centers; Awards and Prizes; Benzamides; Clinical Trials as Topic; Drug Design; Drug Discovery; Drug Industry; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; United States	2009
Shifting paradigms: the seeds of oncogene addiction. Nature medicine, 2009, Volume: 15, Issue:10 Topics: Awards and Prizes; Benzamides; Clinical Trials as Topic; DNA, Complementary; Drug Resistance; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Sequence Analysis, DNA; United States	2009
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PloS one, 2009, Oct-20, Volume: 4, Issue:10 Topics: Antineoplastic Agents; Benzamides; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Models, Chemical; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Tetrazolium Salts; Thiazoles	2009
Anticipating drug resistance in the MAP kinase pathway. Pigment cell & melanoma research, 2010, Volume: 23, Issue:1 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Catalytic Domain; Drug Design; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Neoplasms; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines	2010
Tyrosine kinase inhibitor-induced macrocytosis. Anticancer research, 2009, Volume: 29, Issue:12 Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate	2009
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochimica et biophysica acta, 2010, Volume: 1804, Issue:3 Topics: Adenosine Triphosphate; Allosteric Regulation; Benzamides; Crystallography, X-Ray; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Mutation, Missense; Myristic Acid; Neoplasms; Nuclear Magnetic Resonance, Biomolecular; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines	2010
Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. The Journal of biological chemistry, 2010, Apr-30, Volume: 285, Issue:18 Topics: Animals; Benzamides; Chickens; Computer Simulation; Humans; Imatinib Mesylate; Models, Molecular; Neoplasms; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein-Tyrosine Kinases; Pyrimidines	2010
Counterpoint: Data first. Nature, 2010, Apr-01, Volume: 464, Issue:7289 Topics: Antineoplastic Agents; Benzamides; Drug Discovery; Fusion Proteins, bcr-abl; Genome, Human; Genomics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Precision Medicine; Pyrimidines	2010
Imatinib (Gleevec) as a paradigm of targeted cancer therapies. The Keio journal of medicine, 2010, Volume: 59, Issue:1 Topics: Antineoplastic Agents; Benzamides; Biomedical Research; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines	2010
Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. Molecular cancer therapeutics, 2010, Volume: 9, Issue:5 Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Mice; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Transplantation, Isogeneic; Treatment Outcome	2010
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3 Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome	2011
Targeting targeted therapies. Immunotherapy, 2010, Volume: 2, Issue:6 Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2010
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. The Lancet. Oncology, 2011, Volume: 12, Issue:1 Topics: Antineoplastic Agents; Benzamides; Drug Industry; Drug Monitoring; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2011
16-Hydroxycleroda-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis. Toxicology, 2011, Jul-11, Volume: 285, Issue:1-2 Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Diterpenes; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Serine-Threonine Kinases; Pyrimidines; Signal Transduction	2011
NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Frontiers in bioscience (Elite edition), 2011, 06-01, Volume: 3, Issue:4 Topics: Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mutation; Neoplasms; Phosphorylation; Piperazines; Plant Extracts; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2011
From genome to drugs: where do we stand? Journal of the National Cancer Institute, 2011, Jul-06, Volume: 103, Issue:13 Topics: Antineoplastic Agents; Benzamides; Drug Approval; Drug Design; Drug Industry; Drug Resistance, Neoplasm; Genome, Human; Genomics; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplasms; Orphan Drug Production; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Rare Diseases; Sulfonamides; United States; United States Food and Drug Administration; Vemurafenib	2011
ASCO 2011: broadening the horizons of cancer research. Journal of the National Cancer Institute, 2011, Jul-06, Volume: 103, Issue:13 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Models, Animal; Global Health; Humans; Imatinib Mesylate; Medical Oncology; Mice; Neoplasms; Neoplastic Stem Cells; Piperazines; Pyrimidines; Receptor, ErbB-2; Research; Societies, Medical; Trastuzumab; United States; United States Food and Drug Administration	2011
[Therapeutic adherence to oral cancer therapy and interdisciplinary management]. Revue medicale suisse, 2011, May-25, Volume: 7, Issue:296 Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cecal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Male; Medication Adherence; Neoplasms; Outpatients; Patient-Centered Care; Pharmacists; Physician's Role; Pilot Projects; Piperazines; Prospective Studies; Pyrimidines; Switzerland; Time Factors; Treatment Outcome	2011
miRNAs in the spotlight: Understanding cancer gene dependency. Nature medicine, 2011, Aug-04, Volume: 17, Issue:8 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Imatinib Mesylate; Mice; MicroRNAs; Mutation; Neoplasms; Piperazines; Pyrimidines	2011
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:10 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Imatinib Mesylate; Neoplasms; Netherlands; Pharmacies; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2012
Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Creatine Kinase; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2012
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers? Future medicinal chemistry, 2012, Volume: 4, Issue:11 Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome	2012
Assessment of tracer 99mTc(V)-DMSA uptake as a measure of tumor cell proliferation in vitro. PloS one, 2013, Volume: 8, Issue:1 Topics: Benzamides; Biomarkers; Cell Line, Tumor; Cell Proliferation; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MCF-7 Cells; Neoplasms; Piperazines; Pyrimidines; Radiopharmaceuticals; S Phase; Technetium Tc 99m Dimercaptosuccinic Acid	2013
Changes and challenges--the world post-Gleevec (Glivec). Current opinion in pharmacology, 2002, Volume: 2, Issue:4 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines	2002
[Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]. Bulletin du cancer, 2002, Volume: 89, Issue:6 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Florida; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Skin Neoplasms	2002
Cancer drugs. Smart weapons prove tough to design. Science (New York, N.Y.), 2002, Oct-18, Volume: 298, Issue:5593 Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration	2002
Synthetic lethality: killing cancer with cancer. Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22 Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins	2002
[The new mechanisms and reversal of drug resistance]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Piperazines; Pyrimidines	2003
A new era in cancer therapeutics? Drug discovery today, 2003, Jan-15, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasms; Pharmacogenetics; Piperazines; Pyrimidines	2003
The hypereosinophilic syndrome and the biology of cancer. The New England journal of medicine, 2003, Mar-27, Volume: 348, Issue:13 Topics: Benzamides; Chromosome Deletion; Enzyme Inhibitors; Eosinophilia; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; T-Lymphocytes; Translocation, Genetic	2003
Drug maker's vow to donate cancer medicine falls short. The New York times on the Web, 2003, Jun-05 Topics: Antineoplastic Agents; Benzamides; Developing Countries; Drug Industry; Humans; Imatinib Mesylate; India; Internationality; Neoplasms; Piperazines; Pyrimidines; United States	2003
Combinations of targeted therapies take aim at multiple pathways. Journal of the National Cancer Institute, 2003, Nov-19, Volume: 95, Issue:22 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design	2003
Targeted therapy in cancer and transgenic animal model. Cancer investigation, 2003, Volume: 21, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Breast Neoplasms; Chemoprevention; Disease Models, Animal; Genes, erbB-2; Humans; Imatinib Mesylate; Mice; Mice, Transgenic; Neoplasms; Piperazines; Pyrimidines; Signal Transduction; Trastuzumab	2003
[New reversing agents that target membrane transporters]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2004, Volume: 101, Issue:1 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzamides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Membrane Glycoproteins; Membrane Transport Proteins; Neoplasms; Piperazines; Pyrimidines	2004
Advances in molecular targets and cancer therapeutics. Drug discovery today, 2004, Mar-01, Volume: 9, Issue:5 Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Design; Genomics; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Proteomics; Pyrimidines; Technology, Pharmaceutical	2004
Tyrosine kinase inhibitor STI-571: the new wonder drug of cancer therapy. Cancer biology & therapy, 2004, Volume: 3, Issue:4 Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chemoprevention; Colorectal Neoplasms; Drug Design; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, May-25, Volume: 804, Issue:2 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet	2004
A widening prospect: Imatinib and novel applications of targeted therapy. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction	2004
Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-15, Volume: 10, Issue:12 Pt 1 Topics: Benzamides; Blotting, Western; Gastrointestinal Neoplasms; Gene Expression Regulation; Humans; Imatinib Mesylate; Immunohistochemistry; Isoenzymes; Mesoderm; Neoplasms; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Isoforms; Protein Kinase C; Protein Kinase C-theta; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma; Stromal Cells; T-Lymphocytes; Transcription, Genetic	2004
Imatinib: paradigm or anomaly? Cell cycle (Georgetown, Tex.), 2004, Volume: 3, Issue:7 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Early Diagnosis; Gefitinib; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Receptors, Growth Factor; Signal Transduction	2004
Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST). Medical science monitor : international medical journal of experimental and clinical research, 2004, Volume: 10, Issue:8 Topics: Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2004
Gold standard or wrong standard? Cancer biotherapy & radiopharmaceuticals, 2004, Volume: 19, Issue:3 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2004
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood, 2005, Feb-01, Volume: 105, Issue:3 Topics: Amino Acid Sequence; Animals; Antigen-Presenting Cells; Antineoplastic Agents; Benzamides; Bone Marrow Cells; CD4-Positive T-Lymphocytes; Dendritic Cells; Imatinib Mesylate; Immune Tolerance; Lymphoma; Macrophages; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neoplasms; Ovalbumin; Peptide Fragments; Piperazines; Pyrimidines	2005
[Target-oriented tumor therapy -- proof of the principle]. Deutsche medizinische Wochenschrift (1946), 2004, Oct-01, Volume: 129, Issue:40 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines	2004
Prevalence of KIT expression in human tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-15, Volume: 22, Issue:22 Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasms; Oligonucleotide Array Sequence Analysis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2004
New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. Anti-cancer drugs, 2005, Volume: 16, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; Genes, erbB; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Signal Transduction	2005
[Targeted drugs in radiation therapy]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8 Suppl 1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Trastuzumab; Tumor Cells, Cultured	2004
A functional approach to questions about life, death, and phosphorylation. Cancer cell, 2005, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Survival; Drug Synergism; HeLa Cells; Humans; Imatinib Mesylate; Neoplasms; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; RNA Interference; RNA, Small Interfering	2005
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer biology & therapy, 2005, Volume: 4, Issue:7 Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport; Chlorocebus aethiops; Constitutive Androstane Receptor; COS Cells; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression; Humans; Imatinib Mesylate; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Piperazines; Pregnane X Receptor; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured	2005
Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. Molecular cancer research : MCR, 2005, Volume: 3, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Etoposide; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Neoplasms; Paclitaxel; Phosphorus Radioisotopes; Phosphorylation; Piperazines; Precipitin Tests; Pyrimidines; RNA Helicases; RNA Interference; Stilbenes; Tumor Necrosis Factor-alpha	2005
Imatinib: the narrow line between immune tolerance and activation. Trends in molecular medicine, 2005, Volume: 11, Issue:9 Topics: Adjuvants, Immunologic; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Immune Tolerance; Immunosuppressive Agents; Neoplasms; Piperazines; Pyrimidines	2005
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene, 2006, Jan-05, Volume: 25, Issue:1 Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammation; Inhibitory Concentration 50; Macrophage Colony-Stimulating Factor; Mice; Mutation; Neoplasms; Oncogene Protein v-cbl; Phosphorylation; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-crk; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction; Time Factors; Valine	2006
Drug discovery: playing dirty. Nature, 2005, Oct-13, Volume: 437, Issue:7061 Topics: Animals; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Depression; Drug Approval; Drug Design; Drug Evaluation, Preclinical; Drug Industry; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Sensitivity and Specificity; Substrate Specificity; Therapeutics; United States; United States Food and Drug Administration	2005
Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncology reports, 2006, Volume: 15, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Benzamides; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Enzyme Activation; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Neoplasms; Nuclear Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Up-Regulation	2006
[Current status and prospect of neoplasm targeted therapy]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Design; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Palliative Care; Piperazines; Pyrimidines; Quinazolines; Signal Transduction	2005
Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2006
Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry. Journal of separation science, 2006, Volume: 29, Issue:3 Topics: Animals; Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Erythrocytes; Humans; Imatinib Mesylate; Mass Spectrometry; Molecular Structure; Neoplasms; Piperazines; Pyrimidines	2006
TGFbeta in cancer and other disease - AACR special conference in cancer research. IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:4 Topics: Animals; Antibodies, Monoclonal; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Oligonucleotides, Antisense; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transforming Growth Factor beta; Transforming Growth Factor beta2	2006
[The diagnostic and predictive role of kit (CD117)]. Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4 Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Genetic Markers; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mutation; Neoplasms; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sensitivity and Specificity; Signal Transduction	2006
Imatinib mesylate--uncovering a fast track to adaptive immunity. The New England journal of medicine, 2006, May-25, Volume: 354, Issue:21 Topics: Adoptive Transfer; Animals; Benzamides; Cytotoxicity, Immunologic; Dendritic Cells; Imatinib Mesylate; Interferon-gamma; Interferons; Killer Cells, Natural; Mice; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2006
Targeting tyrosine kinases in cancer: the second wave. Science (New York, N.Y.), 2006, May-26, Volume: 312, Issue:5777 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, ErbB-2; Receptors, Platelet-Derived Growth Factor; Trastuzumab	2006
Ongoing challenges of a global international patient assistance program. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 8 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Developing Countries; Gastrointestinal Stromal Tumors; Global Health; Health Services Accessibility; Humans; Imatinib Mesylate; International Cooperation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Program Development; Program Evaluation; Public Health; Pyrimidines; Thailand	2006
Targeted cancer therapeutics: the heartbreak of success. Nature medicine, 2006, Volume: 12, Issue:8 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Enzyme Inhibitors; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplasms; Piperazines; Pyrimidines; src-Family Kinases; Ventricular Dysfunction, Left	2006
Antivascular therapy of cancer metastasis. Journal of surgical oncology, 2006, Sep-01, Volume: 94, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor	2006
Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells. Journal of immunology (Baltimore, Md. : 1950), 2006, Sep-01, Volume: 177, Issue:5 Topics: Animals; Benzamides; Cell Differentiation; Cells, Cultured; Coculture Techniques; Dendritic Cells; Galactosylceramides; Humans; Imatinib Mesylate; Interferon-gamma; Interleukin-12; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Mice; Monocytes; Neoplasms; Piperazines; Pyrimidines; T-Lymphocytes, Regulatory	2006
Pharmacy benefit spending on oral chemotherapy drugs. Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7 Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States	2006
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer research, 2006, Dec-01, Volume: 66, Issue:23 Topics: Aniline Compounds; Animals; Benzamides; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; K562 Cells; Mice; Mice, Nude; Models, Molecular; Mutation; Neoplasms; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; src-Family Kinases; Survival Analysis; Thiazoles; U937 Cells; Xenograft Model Antitumor Assays	2006
EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Pediatric drugs, biomarkers and new therapies. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; Drug Design; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasms; Piperazines; Pyrimidines	2007
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature medicine, 2007, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines	2007
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature medicine, 2007, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines	2007
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature medicine, 2007, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines	2007
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature medicine, 2007, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines	2007
New insights into oncogene addiction found. Journal of the National Cancer Institute, 2007, Feb-21, Volume: 99, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab	2007
Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Molecular therapy : the journal of the American Society of Gene Therapy, 2007, Volume: 15, Issue:5 Topics: Adenoviridae; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clodronic Acid; Genetic Therapy; Genetic Vectors; Humans; Imatinib Mesylate; Immunohistochemistry; Kinetics; Liver; Luciferases; Luminescent Measurements; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Neoplasms; Phosphorylation; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tissue Distribution	2007
Cancer therapy: new drugs are emerging based on molecular targeting but still many challenges. The international journal of biochemistry & cell biology, 2007, Volume: 39, Issue:7-8 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Oncogenes; Piperazines; Pyrimidines; TNF-Related Apoptosis-Inducing Ligand	2007
Unexplored pharmacokinetic opportunities with microdosing in oncology. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jul-15, Volume: 13, Issue:14 Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines	2007
Progressive thoughts about progressive disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 1 Topics: Antineoplastic Agents; Benzamides; Clone Cells; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines	2007
In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. Biopharmaceutics & drug disposition, 2008, Volume: 29, Issue:2 Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Benzamides; Biotransformation; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Humans; Imatinib Mesylate; Kinetics; Mass Spectrometry; Neoplasms; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines	2008
Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Molecular biology of the cell, 2008, Volume: 19, Issue:5 Topics: Angiogenesis Inducing Agents; Animals; Benzamides; Cell Line; Cell Proliferation; Cytoplasm; Cytoskeleton; Endothelial Cells; Enzyme Activation; Fibroblast Growth Factor 2; Humans; Imatinib Mesylate; Mice; Mice, SCID; Models, Biological; Mutant Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Signal Transduction; Vascular Endothelial Growth Factor A	2008
Telomerase inhibition combined with other chemotherapeutic reagents to enhance anti-cancer effect. Methods in molecular biology (Clifton, N.J.), 2007, Volume: 405 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Synergism; Humans; Imatinib Mesylate; K562 Cells; Neoplasms; Oxazoles; Piperazines; Pyrimidines; Telomerase	2007
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 2001, Apr-01, Volume: 97, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Microbial Sensitivity Tests; Neoplasm Proteins; Neoplasms; Piperazines; Pyrimidines; Tumor Cells, Cultured; Vincristine	2001
New hope for cancer. Time, 2001, May-28, Volume: 157, Issue:21 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Drug Industry; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; United States	2001
Researchers optimistic about sea change in cancer treatment. JAMA, 2001, Jun-13, Volume: 285, Issue:22 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Medical Oncology; Neoplasms; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases	2001
STI571 revolution: can the newer targeted drugs measure up? Journal of the National Cancer Institute, 2001, Jul-04, Volume: 93, Issue:13 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasms; Piperazines; Pyrimidines	2001
Cancer treatment. New drugs, new hope. Harvard health letter, 2001, Volume: 26, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma	2001
92nd Annual Meeting of the American Association for Cancer Research. 24-28 March, 2001, New Orleans, Louisiana, USA. Expert opinion on investigational drugs, 2001, Volume: 10, Issue:6 Topics: Animals; Benzamides; Carrier Proteins; Clinical Trials as Topic; Dimethylallyltranstransferase; Enzyme Inhibitors; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Pyrimidines; Societies, Medical; United States	2001
The advent of targeted therapeutics and implications for pathologists. American journal of clinical pathology, 2002, Volume: 117, Issue:3 Topics: Antineoplastic Agents; Benzamides; Drug Design; Humans; Imatinib Mesylate; Neoplasms; Pathology; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2002
On the offensive. Nature, 2002, Apr-04, Volume: 416, Issue:6880 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Research	2002